Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program (vol 22, pg 693, 2021)

被引：1

作者：

Simpson, Eric L. ^{[1
]}

Silverberg, Jonathan I. ^{[2
]}

Nosbaum, Audrey ^{[3
]}

Winthrop, Kevin L. ^{[1
]}

Guttman-Yassky, Emma ^{[4
]}

Hoffmeister, Karin M. ^{[5
,6
]}

Egeberg, Alexander ^{[7
]}

Valdez, Hernan ^{[8
]}

Zhang, Min ^{[9
]}

Farooqui, Saleem A. ^{[10
]}

Romero, William ^{[11
]}

Thorpe, Andrew J. ^{[12
]}

Rojo, Ricardo ^{[13
]}

Johnson, Susan ^{[12
]}

机构：

[1] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA

[2] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC 20052 USA

[3] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Dept Allergy & Clin Immunol, Pierre Benite, France

[4] Icahn Sch Med Mt Sinai, Dept Dermatol & Immunol, New York, NY 10029 USA

[5] Blood Res Inst, Versiti Translat Glyc Ctr, Milwaukee, WI USA

[6] Med Coll Wisconsin, Dept Biochem & Med, Milwaukee, WI 53226 USA

[7] Univ Copenhagen, Bispebjerg Hosp, Dept Dermatol, Copenhagen, Denmark

[8] Pfizer Inc, New York, NY USA

[9] Pfizer Inc, La Jolla, CA USA

[10] Pfizer R&D UK Ltd, Kent, OH USA

[11] Pfizer Ltd, Surrey, England

[12] Pfizer Inc, Collegeville, PA 19426 USA

[13] Pfizer Inc, Groton, CT 06340 USA

来源：

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY | 2021年 / 22卷 / 06期

关键词：

D O I：

10.1007/s40257-021-00638-z

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

下载

页码：905 / 905

页数：1

共 50 条

[41] Efficacy and Safety of Abrocitinib in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN study
Eichenfield, Lawrence
Flohr, Carsten
Sidbury, Robert
Szalai, Zsuzsanna
Galus, Ryszard
Yao, Zhirong
Takahashi, Hidetoshi
Barbarot, S. Ebastien
Feeney, Claire
Zhang, Fan
DiBonaventura, Marco
Rojo, Ricardo
Valdez, Hernan
Chan, Gary
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB146 - AB146
[42] Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial
Blauvelt, Andrew
Silverberg, Jonathan, I
Lynde, Charles W.
Bieber, Thomas
Eisman, Samantha
Zdybski, Jacek
Gubelin, Walter
Simpson, Eric L.
Valenzuela, Fernando
Criado, Paulo Ricardo
Lebwohl, Mark G.
Feeney, Claire
Khan, Tahira
Biswas, Pinaki
DiBonaventura, Marco
Valdez, Hernan
Cameron, Michael C.
Rojo, Ricardo
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (01) : 104 - 112
[43] Efficacy and safety of abrocitinib in adolescent patients with moderate-to-severe atopic dermatitis: stratified analysis across three clinical trials
Simpson, E.
Lio, P.
Heath, C.
Boguniewicz, M.
Levenberg, M.
Biswas, P.
Farooqui, S.
Kerkmann, U.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E140 - E140
[44] Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis The JADE TEEN Randomized Clinical Trial
Eichenfield, Lawrence F.
Flohr, Carsten
Sidbury, Robert
Siegfried, Elaine
Szalai, Zsuzsanna
Galus, Ryszard
Yao, Zhirong
Takahashi, Hidetoshi
Barbarot, Sebastien
Feeney, Claire
Zhang, Fan
DiBonaventura, Marco
Rojo, Ricardo
Valdez, Hernan
Chan, Gary
JAMA DERMATOLOGY, 2021, 157 (10) : 1165 - 1173
[45] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials
Tofte, Susan J.
Papp, Kim
Sadick, Neil
Bohnert, Krista
Simpson, Eric
Thaci, Diamant
Bieber, Thomas
Blauvelt, Andrew
Sofen, Howard
Gooderham, Melinda
Chen, Zhen
Gadkari, Abhijit
Eckert, Laurent
Graham, Neil M. H.
Pirozzi, Gianluca
Ardeleanu, Marius
JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2018, 30 (09): : 529 - 541
[46] Patient-reported outcomes with abrocitinib treatment in patients with moderate to severe atopic dermatitis: Results from a randomized, phase 3 clinical trial
Silverberg, Jonathan I.
Cohen, Arnon D.
Stander, Sonja
Feeney, Claire
Valdez, Hernan
Biswas, Pinaki
Cameron, Michael C.
DiBonaventura, Marco
Gerber, Robert A.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB35 - AB35
[47] Integrated Safety Analysis of Abrocitinib in 3802 Patients With Moderate-To-Severe Atopic Dermatitis With Over 5000 Patient-Years of Exposure
Simpson, Eric L.
Silverberg, Jonathan I.
Nosbaum, Audrey
Winthrop, Kevin
Guttman-Yassky, Emma
Egeberg, Alexander
Fan, Haiyun
Alderfer, Justine
Johnson, Susan L.
Farooqui, Saleem A.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB58 - AB58
[48] Methotrexate Versus Cyclosporine in Adults with Moderate-to-Severe Atopic Dermatitis: A Phase III Randomized Noninferiority Trial
Goujon, Catherine
Viguier, Manuelle
Staumont-Salle, Delphine
Bernier, Claire
Guillet, Gerard
Lahfa, Morad
Le Bouedec, Marie-Christine Ferrier
Cambazard, Frederic
Bottigioli, David
Grande, Sophie
Dahel, Karima
Berard, Frederic
Rabilloud, Muriel
Mercier, Catherine
Nicolas, Jean-Francois
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2018, 6 (02): : 562 - +
[49] Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial
Staender, Sonja
Kwatra, Shawn G.
Silverberg, Jonathan, I
Simpson, Eric L.
Thyssen, Jacob P.
Yosipovitch, Gil
Zhang, Fan
Cameron, Michael C.
Cella, Ricardo Rojo
Valdez, Hernan
DiBonaventura, Marco
Feeney, Claire
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2023, 24 (01) : 97 - 107
[50] Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial
Sonja Ständer
Shawn G. Kwatra
Jonathan I. Silverberg
Eric L. Simpson
Jacob P. Thyssen
Gil Yosipovitch
Fan Zhang
Michael C. Cameron
Ricardo Rojo Cella
Hernan Valdez
Marco DiBonaventura
Claire Feeney
American Journal of Clinical Dermatology, 2023, 24 : 97 - 107

← 1 2 3 4 5 →